Luo Ying Files 13D for Gyre Therapeutics
Ticker: GYRE · Form: SC 13D · Filed: Sep 6, 2024 · CIK: 1124105
| Field | Detail |
|---|---|
| Company | Gyre Therapeutics, Inc. (GYRE) |
| Form Type | SC 13D |
| Filed Date | Sep 6, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 13D-filing, ownership-change, pharmaceuticals
TL;DR
**GYRE THERAPEUTICS:** Luo Ying just filed a 13D. Big changes coming?
AI Summary
On September 6, 2024, Luo Ying filed a Schedule 13D for Gyre Therapeutics, Inc. (formerly Catalyst Bioscience, Inc. and Targacept Inc.). The filing indicates a change in beneficial ownership, though specific share amounts and dollar values are not detailed in this excerpt. The filing address for Gyre Therapeutics is 12770 High Bluff Drive, Suite 150, San Diego, California.
Why It Matters
This filing signals a potential shift in control or significant stake acquisition in Gyre Therapeutics, which could impact the company's strategic direction and stock performance.
Risk Assessment
Risk Level: medium — Schedule 13D filings often precede significant corporate actions or changes in control, introducing uncertainty.
Key Players & Entities
- Luo Ying (person) — Filing person
- Gyre Therapeutics, Inc. (company) — Subject company
- Catalyst Bioscience, Inc. (company) — Former company name
- Targacept Inc (company) — Former company name
- 0001140361-24-040313 (document_id) — Accession number for the filing
FAQ
Who is Luo Ying and what is their relationship to Gyre Therapeutics?
Luo Ying is the filing person for this Schedule 13D. Their specific role or prior relationship with Gyre Therapeutics is not detailed in this excerpt.
What is the significance of a Schedule 13D filing?
A Schedule 13D filing is required when a person or group acquires beneficial ownership of more than 5% of a company's voting stock, indicating a significant investment or potential change in control.
When was this filing made?
The filing was made on September 6, 2024.
What were Gyre Therapeutics' former names?
Gyre Therapeutics, Inc. was formerly known as Catalyst Bioscience, Inc. and Targacept Inc.
What is the business address of Gyre Therapeutics?
The business address is 12770 High Bluff Drive, Suite 150, San Diego, California, 92130.
Filing Stats: 1,865 words · 7 min read · ~6 pages · Grade level 10.1 · Accepted 2024-09-06 08:15:45
Key Financial Figures
- $0.001 — ame of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securitie
Filing Documents
- ef20035610_sc13d.htm (SC 13D) — 81KB
- ef20035610_ex99-1.htm (EX-99.1) — 5KB
- 0001140361-24-040313.txt ( ) — 87KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date : September 6, 2024 /s/ Ying Luo YING LUO /s/ Ping Lan PING LAN